stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Return on assets
Biogen Inc.'s return on assets over the twelve months to 30 September 2026 was 1.13%, down 3.4 percentage points from fiscal 2025 (4.50%). Over the past ten years it has ranged from 4.50% (fiscal 2025) to 22.4% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 4.50% | (1.45) |
| FY2024 | 5.95% | 1.43 |
| FY2023 | 4.52% | (8.06) |
| FY2022 | 12.6% | 6.16 |
| FY2021 | 6.42% | (9.01) |
| FY2020 | 15.4% | (6.99) |
| FY2019 | 22.4% | 4.31 |
| FY2018 | 18.1% | 7.20 |
| FY2017 | 10.9% | (6.56) |
| FY2016 | 17.5% | (3.51) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 22.0% |
| AMGN Amgen Inc. compare | 10.1% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| AZN AstraZeneca PLC compare | 9.41% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi compare | 3.24% |
| PFE Pfizer Inc. compare | 1.95% |
| BIIB Biogen Inc. | 1.13% |
| GILD Gilead Sciences, Inc. compare | −7.03% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement